Skip to content

Moderna and Merck say mRNA vaccine prevents melanoma relapse in trial

scienceAug 19, 2026151,825

Moderna and Merck reported Phase 3 trial results showing their personalized mRNA vaccine, given with pembrolizumab, significantly extended the time high-risk melanoma patients lived without recurrence and lowered the risk of the cancer spreading. The companies said the vaccine prevented melanoma from returning and metastasizing in the trial population of more than 1,100 patients. News coverage and commentators noted the announcement so far comes as a company release and urged publication of the full peer-reviewed paper and independent review of the data. Coverage quoted voices saying the treatment paradigm could be extendable to other cancers. Some posts linked the news to political controversy, with claims that RFK Jr. canceled $500 million in mRNA vaccine research funding. Next steps described in reporting are publication of the detailed trial data and expert assessment of the results.

Chise
@sailorrooscout.bsky.social

GOOD NEWS! A personalized mRNA vaccine has SUCCEEDED in keeping melanoma, a deadly skin cancer, from returning. Phase III trial results in MORE THAN 1,100 patients shows the vaccine SIGNIFICANTLY extended the time patients lived without their melanoma returning AND reduced the risk of metastasis.

15044h ago
1 source